Axel Merseburger, MD, PhD, spoke about implementing the treatment combination of enzalutamide plus docetaxel/prednisone for progressive castration-resistant prostate cancer from the PRESIDE trial into the real-world.
Axel Merseburger, MD, PhD
Advertisement
Articles by Axel Merseburger, MD, PhD
Axel Merseburger, MD, PhD, looked back on 2022 ASCO GU and the new data presented for the treatment of prostate cancer.
Axel Merseburger, MD, PhD, spoke key results of the PRESIDE trial, which examined continuous enzalutamide to treat patients with metastatic castration-resistant prostate cancer and progressive disease.
Advertisement
Latest Updated Articles
Merseburger Offers PRESIDE Trial Overview of Continuous Enzalutamide in mCRPCPublished: February 23rd 2022 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
2
Response Rates Show Promise in Phase 1 trial Involving ASCT in Metastatic PDAC
3
What Path to Approval Has Dasatinib Taken in CML/ALL?
4
JSKN003 Receives FDA Fast Track Designation in Advanced PROC
5
